Order Article Reprints

Subtil FSB, Gröbner C, Recknagel N, Parplys AC, Kohl S, Arenz A, Eberle F, Dikomey E, Engenhart-Cabillic R, Schötz U. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines. Cancers. 2022; 14(13):3160. https://doi.org/10.3390/cancers14133160

Subtil, Florentine S. B., Carolin Gröbner, Niklas Recknagel, Ann Christin Parplys, Sibylla Kohl, Andrea Arenz, Fabian Eberle, Ekkehard Dikomey, Rita Engenhart-Cabillic, and Ulrike Schötz. 2022. "Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines" Cancers 14, no. 13: 3160. https://doi.org/10.3390/cancers14133160

Subtil, F. S. B., Gröbner, C., Recknagel, N., Parplys, A. C., Kohl, S., Arenz, A., Eberle, F., Dikomey, E., Engenhart-Cabillic, R., & Schötz, U. (2022). Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines. Cancers, 14(13), 3160. https://doi.org/10.3390/cancers14133160